Bioniche Pharma, a leading developer and manufacturer of injectable pharmaceuticals, announced the acquisition of Duraclon (clonidine hydrochloride injection) and Methadone Hydrochloride Injection USP from Xanodyne Pharmaceuticals, Inc.

"Bioniche Pharma is very pleased to expand our product line with these injectable drugs," said Steve Thornton, Bioniche Pharma CEO. "These two products represent our commitment to expanding our product line with a combination of brand and generic drugs, which strengthens our position as a specialty injectables pharmaceutical company."

Duraclon (clonidine hydrochloride injection) has a black box warning relating to risk of hemodynamic instability, especially hypotension and bradycardia in obstetrical, postpartum and peri-operative pain management. Methadone Hydrochloride Injection USP has black box warnings relating to peri-operative pain management and to conditions for distribution and use for the treatment of opioid addiction.

Bioniche Pharma is a global manufacturer of injectable pharmaceutical products serving a variety of niche markets, with expertise in injectable hyaluronic acid products for use in orthopaedics, rheumatology, urology, and dermatology. An internal development pipeline and an aggressive acquisition strategy for products fuel the company's growth.